Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial

作者：Xiaohua Wu, Jihong Liu, Jing Wang, Li Wang, Zhongqiu Lin, Xiaobin Wang, Jianqing Zhu, Beihua Kong, Junwei Fei, Ying Tang, Bairong Xia, Zhiqing Liang, Ke Wang, Yi Huang, Hong Zheng, Lin An, Kui Jiang, Wei Wang, Xin Wang, Ge Lou, Hongming Pan, Shuzhong Yao, Guiling Li, Min Hao, Yunlang Cai, Xuejun Chen, Zhijun Yang, Youguo Chen, Hongwu Wen, Pengpeng Qu, Cong Xu, Chih-Yi Hsieh, the FLAMES Investigators, Manhua Cui, Lipai Chen, Ying Cheng, Weidong Zhao, Mei Pan, Yaling Tang, Yu Zhang, Xiaoyan Lin, Guzhalinuer Abulizi, Wei Duan, Linjuan Zeng · 发表于：Nature Medicine · 年份：2024 · DOI：10.1038/s41591-024-03003-9 · 被引用次数：41 · 研究领域：PARP inhibition in cancer therapy、Ovarian cancer diagnosis and treatment、Toxin Mechanisms and Immunotoxins